JW Pharmaceutical Corporation (KRX:001065)
South Korea flag South Korea · Delayed Price · Currency is KRW
29,100
+100 (0.34%)
Feb 5, 2026, 2:00 PM KST

JW Pharmaceutical Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
62,78865,04037,00631,892-967.85-15,241
Depreciation & Amortization
18,73819,10122,57516,83616,11220,688
Loss (Gain) From Sale of Assets
-440.1-464.911,088-3.281,04812.24
Asset Writedown & Restructuring Costs
1,4761,476-4,821--
Loss (Gain) From Sale of Investments
-446.66-790.9-2,8308,5151,820-
Loss (Gain) on Equity Investments
-1,684-1,387-621.061,3491,1491,924
Provision & Write-off of Bad Debts
-2,928-6,081-3,6448,43712,0736,870
Other Operating Activities
7,19511,78253,846-8,91332,94613,584
Change in Accounts Receivable
15,65229,965-4,734-4,312-41,56645,208
Change in Inventory
587.03-8,7758,917-11,541-2,655-8,876
Change in Accounts Payable
-1,176-14,527-9,53631,6523,7302,831
Change in Unearned Revenue
---153.66-53.5--199.22
Change in Other Net Operating Assets
-11,965-15,946-14,756-21,915-5,564-3,747
Operating Cash Flow
87,79579,39287,15756,76418,12463,054
Operating Cash Flow Growth
-7.66%-8.91%53.54%213.20%-71.26%13.55%
Capital Expenditures
-9,771-8,313-27,286-9,919-7,467-12,387
Sale of Property, Plant & Equipment
61.3446.424.976.2663,44665.58
Cash Acquisitions
-138.7-138.7-12,005-40.88--
Divestitures
----384.96-
Sale (Purchase) of Intangibles
-19,757-17,734-13,419-2,433-5,435-2,652
Investment in Securities
27,16631,7258,260-26,3441,078-61,955
Other Investing Activities
-3,757358.72-6,355267.37-44,541501.19
Investing Cash Flow
3,84314,085-63,780-18,919-22,869-79,427
Short-Term Debt Issued
-104,737227,876110,89675,32394,683
Long-Term Debt Issued
-25,10260,16629,58560,29670,000
Total Debt Issued
99,200129,839288,042140,481135,619164,683
Short-Term Debt Repaid
--171,805-316,108-177,004-84,408-142,087
Long-Term Debt Repaid
--47,809-4,051-2,795-16,845-29,427
Total Debt Repaid
-176,419-219,613-320,159-179,799-101,254-171,515
Net Debt Issued (Repaid)
-77,220-89,774-32,117-39,31834,365-6,831
Issuance of Common Stock
---10,000398.47-
Repurchase of Common Stock
-9,958-750.42-260.88-281.6-412.29-224.25
Common Dividends Paid
-11,068-9,665-8,814-7,352-7,149-6,954
Other Financing Activities
-0-0-5444-0-
Financing Cash Flow
-98,246-100,190-41,245-36,90727,202-14,009
Foreign Exchange Rate Adjustments
393.551,234-120.69-406.38458.72-1,031
Miscellaneous Cash Flow Adjustments
0-----
Net Cash Flow
-6,214-5,479-17,989531.4522,915-31,413
Free Cash Flow
78,02471,07959,87146,84510,65750,667
Free Cash Flow Growth
-9.65%18.72%27.81%339.56%-78.97%9.56%
Free Cash Flow Margin
10.21%9.88%8.00%6.84%1.76%9.26%
Free Cash Flow Per Share
3376.743047.372515.252016.97459.202182.01
Cash Interest Paid
3,9158,13611,1199,0357,5677,640
Cash Income Tax Paid
31,33816,58713,33531,621863.42-1,417
Levered Free Cash Flow
61,42341,86423,38174,265-6,67254,565
Unlevered Free Cash Flow
67,69448,13531,23280,132-2,08759,307
Change in Working Capital
3,097-9,283-20,263-6,170-46,05635,217
Source: S&P Global Market Intelligence. Standard template. Financial Sources.